Document is current
Any future updates will be listed below
-
Authors
Ramos, Hugo https://orcid.org/0000-0001-6443-7576
Augustine, Josy https://orcid.org/0000-0001-5178-5029
Karan, Burak M. https://orcid.org/0000-0002-9362-9267
Hernández, Cristina https://orcid.org/0000-0002-3109-1721
Stitt, Alan W. https://orcid.org/0000-0002-8647-9918
Curtis, Tim M. https://orcid.org/0000-0003-1543-2781
Simó, Rafael https://orcid.org/0000-0003-0475-3096
-
Funding
Funding for this research was provided by:
EAsDEC Skills Award Program
Belfast Association for the Blind
Diabetes UK (18/0005791)
Biotechnology and Biological Sciences Research Council (BB/I026359/1)
Ministerio de Ciencia e Innovación (PID2022-138544OB-I00)
Instituto de Salud Carlos III (ICI20/00129)
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 30 October 2024
First Online: 30 November 2024
Declarations
:
: Animal experiments were approved by the Animal Welfare Ethical Review Body (AWERB) of Queen’s University Belfast. The protocol complied with the UK Home Office Animals (Scientific Procedures) Act 1986 (project license, PPL2888) and the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmology and vision research.
: Two of the authors (Cristina Hernández and Rafael Simó) are inventors of the patent PCT/EP2017/060234, which is related to use of dipeptidyl peptidase-4 inhibitors (sitagliptin) for topical eye treatment of retinal neurodegenerative diseases.
